Drugs, Developed

In an era of instant communication, we must be careful how word of new and untested treatments is shared.

Written byBob Grant
| 3 min read
anesthesia 2019 march editorial

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: andrzej krauze

Iam no fan of anesthesia. The feeling of being rendered unconscious to facilitate the manipulation of my body, only to be reanimated afterward, gives me, like many people (I assume), the heebie-jeebies. But alas, anesthesia is a medical necessity. It has made lifesaving surgeries and once-dreaded dental procedures pain-free and relatively routine for more than 150 years. My own medical care, not to mention that of billions of other people and animals, has benefited greatly from this chemical control of consciousness.

Beyond my personal misgivings, anesthesia’s development into a widely accepted medical protocol illustrates an interesting, if outmoded, avenue of innovation—let’s call it efficacy sans mechanism. As described here by scientists Emery Brown and Francisco Flores in their dispatch from the front lines of anesthesia research, in the mid-19th century, dentist William Morton successfully put a patient under general anesthesia (using ether vapor, in this case) in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Published In

March 2019

Going Under

Dissecting the effects of anesthetics

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies